Pricing
  1. US-listed companies
  2. Emergent BioSolutions Inc.
  3. Financials
  4. Total liabilities

Emergent BioSolutions Inc. (EBS)

Market cap
$446.71M
P/E ratio
SummaryFinancials
Period EndTotal liabilities (Million USD)YoY (%)
Dec 31, 2024907-22.74%
Dec 31, 20231,174-34.18%
Dec 31, 20221,784+33.10%
Dec 31, 20211,340-6.70%
Dec 31, 20201,436+15.93%
Dec 31, 20191,239+1.67%
Dec 31, 20181,219+671.88%
Dec 31, 2017158-57.78%
Dec 31, 2016374-2.52%
Dec 31, 2015384+179.03%
Dec 31, 2013137+12.58%
Dec 31, 2012122-6.17%
Dec 31, 2011130

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat